23.03.2020 • NewsElaine BurridgeTecnimont

Tecnimont Wins Turkey Fertilizer Project

(c)  Maire Tecnimont
(c) Maire Tecnimont

Tecnimont, part of Italy’s Maire Tecnimont group, has signed a contract worth about €200 million to provide engineering, procurement and construction services to Gubre Sanayii Anonim Sirketi’s fertilizer project in Turkey.

The contractor will build a urea and urea ammonium nitrate (UAN) solution plant in Gemlik, south of Istanbul, based on technology from Stamicarbon, a fully-owned subsidiary of Maire Tecnimont. The plant will have capacities of 1,640 t/d granular urea and 500 t/d UAN.

Completion is expected within about three years of the contract taking effect.

Maire Tecnimont’s CEO Pierroberto Folgiero said the contract allows the engineering company to expand its geographical footprint in the strategic market of Turkey.

Gubre Sanayii Anonim Sirketi is part of Yildirim Holding, a multi-billion-dollar diversified group that is active in many fields ranging from chemicals and fertilizers to ports and logistics, metals and mining.

Tecnimont is also providing services on another fertilizer plant, notably for EuroChem in Kingisepp, northwest Russia, under a deal signed last October. Initially, the contractor is performing engineering and site survey work at the brownfield site with the expectation of extending the contract into engineering, procurement and construction services.

The complex will produce about 3,000 t/y ammonia and 4,000 t/d urea. A start-up date has not been disclosed.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read